# ClinicalTrials.gov record NCT03043807

> PeptideScanner retained ClinicalTrials.gov record NCT03043807 at 2026-07-30T19:16:22.177Z. Its registry update date was 2023-02-16, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct03043807-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-02-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03043807-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03043807-leuprolide-v1.json
- Content SHA-256: `e16cbcb446fe1eaa90c5d7f2c6e4e0d4f41bfd58a5521141cc699430c751a994`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT03043807 ([`ctg-observation-nct03043807-2023-02-16-badb01aaa4f6`](#source-ctg-observation-nct03043807-2023-02-16-badb01aaa4f6))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03043807 at 2026-07-30T19:16:22.177Z. Its registry update date was 2023-02-16, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct03043807-2023-02-16-badb01aaa4f6`](#source-ctg-observation-nct03043807-2023-02-16-badb01aaa4f6))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03043807 at 2026-07-30T19:16:22.177Z. Its registry update date was 2023-02-16, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct03043807-2023-02-16-badb01aaa4f6`](#source-ctg-observation-nct03043807-2023-02-16-badb01aaa4f6))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03043807-2023-02-16-badb01aaa4f6`](#source-ctg-observation-nct03043807-2023-02-16-badb01aaa4f6))

## Sources

<a id="source-ctg-observation-nct03043807-2023-02-16-badb01aaa4f6"></a>
- **ClinicalTrials.gov record NCT03043807 · retained source version 2023-02-16:badb01aaa4f67d045b6a2b9af505ed2fc25e645be40213f0402fe8b0d2da0ebe** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03043807) (`ctg-observation-nct03043807-2023-02-16-badb01aaa4f6`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03043807." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03043807-leuprolide-v1.json SHA-256: e16cbcb446fe1eaa90c5d7f2c6e4e0d4f41bfd58a5521141cc699430c751a994.

